英夫利昔单抗与IBD患者SARS-CoV-2疫苗免疫原性减弱相关
该研究比较了英夫利昔单抗治疗(n=865)与维得利珠单抗治疗(n=428)的炎症性肠病患者接种单剂BNT162b2或ChAdOx1 nCoV-19疫苗后的抗体反应。结果显示英夫利昔单抗组抗SARS-CoV-2刺突抗体浓度显著低于维得利珠单抗组,既往感染或接种第二剂BNT162b2后多数患者可发生血清转换,提示应避免延迟第二剂接种。
要点
- 英夫利昔单抗治疗者单剂疫苗接种后抗SARS-CoV-2抗体浓度低于维得利珠单抗治疗者。
- 既往SARS-CoV-2感染或接种第二剂BNT162b2后多数患者可发生血清转换。
- 接受英夫利昔单抗治疗的患者应避免延迟第二剂疫苗接种。
核心结论
- 英夫利昔单抗与单剂BNT162b2和ChAdOx1 nCoV-19 SARS-CoV-2疫苗免疫原性减弱相关。
- 既往SARS-CoV-2感染后接种或接种第二剂疫苗可使多数患者发生血清转换。
- 接受英夫利昔单抗治疗的患者应避免延迟第二剂接种。
研究设计与样本
- 比较英夫利昔单抗治疗患者(n=865)与维得利珠单抗治疗患者(n=428)的抗体应答和血清转换率。
- 主要结局为无既往感染证据者接种后3-10周用Elecsys抗SARS-CoV-2刺突抗体检测法测定的抗SARS-CoV-2刺突抗体浓度。
- 次要结局为血清转换率( cut-off 15 U/mL)及既往感染或第二剂BNT162b2后的抗体应答。
主要发现
- BNT162b2接种后,英夫利昔单抗组几何平均抗SARS-CoV-2抗体浓度为6.0 U/mL(SD 5.9),维得利珠单抗组为28.8 U/mL(SD 5.4),p<0.0001。
- ChAdOx1 nCoV-19接种后,英夫利昔单抗组为4.7 U/mL(SD 4.9),维得利珠单抗组为13.8 U/mL(SD 5.9),p<0.0001。
- 多变量模型中,英夫利昔单抗组较维得利珠单抗组抗体浓度更低:BNT162b2的FC 0.29(95%CI 0.21-0.40),p<0.0001;ChAdOx1 nCoV-19的FC 0.39(95%CI 0.30-0.51),p<0.0001。
- 年龄≥60岁、免疫调节剂使用、克罗恩病和吸烟与较低抗体浓度相关,非白人种族与较高抗体浓度相关。
- 单剂任一疫苗后,既往SARS-CoV-2感染者和接种两剂BNT162b2者血清转换率更高。
关键数值与推荐
- 血清转换定义为抗体 cut-off 15 U/mL。
- 抗体检测时间为接种后3-10周,采用Elecsys抗SARS-CoV-2刺突抗体检测法。
临床怎么用
- 对接受英夫利昔单抗治疗的IBD患者,应避免延迟第二剂SARS-CoV-2疫苗接种。
- 既往SARS-CoV-2感染或完成两剂BNT162b2接种可提高血清转换率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Delayed second dose SARS-CoV-2 vaccination trades maximal effectiveness for a lower level of immunity across more of the population. We investigated whether patients with inflammatory bowel disease treated with infliximab have attenuated serological responses to a single dose of a SARS-CoV-2 vaccine. DESIGN: Antibody responses and seroconversion rates in infliximab-treated patients (n=865) were compared with a cohort treated with vedolizumab (n=428), a gut-selective anti-integrin α4β7 monoclonal antibody. Our primary outcome was anti-SARS-CoV-2 spike (S) antibody concentrations, measured using the Elecsys anti-SARS-CoV-2 spike (S) antibody assay 3-10 weeks after vaccination, in patients without evidence of prior infection. Secondary outcomes were seroconversion rates (defined by a cut-off of 15 U/mL), and antibody responses following past infection or a second dose of the BNT162b2 vaccine. RESULTS: Geometric mean (SD) anti-SARS-CoV-2 antibody concentrations were lower in patients treated with infliximab than vedolizumab, following BNT162b2 (6.0 U/mL (5.9) vs 28.8 U/mL (5.4) p<0.0001) and ChAdOx1 nCoV-19 (4.7 U/mL (4.9)) vs 13.8 U/mL (5.9) p<0.0001) vaccines. In our multivariable models, antibody concentrations were lower in infliximab-treated compared with vedolizumab-treated patients who received the BNT162b2 (fold change (FC) 0.29 (95% CI 0.21 to 0.40), p<0.0001) and ChAdOx1 nCoV-19 (FC 0.39 (95% CI 0.30 to 0.51), p<0.0001) vaccines. In both models, age ≥60 years, immunomodulator use, Crohn's disease and smoking were associated with lower, while non-white ethnicity was associated with higher, anti-SARS-CoV-2 antibody concentrations. Seroconversion rates after a single dose of either vaccine were higher in patients with prior SARS-CoV-2 infection and after two doses of BNT162b2 vaccine. CONCLUSION: Infliximab is associated with attenuated immunogenicity to a single dose of the BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines. Vaccination after SARS-CoV-2 infection, or a second dose of vaccine, led to seroconversion in most patients. Delayed second dosing should be avoided in patients treated with infliximab. TRIAL REGISTRATION NUMBER: ISRCTN45176516.
引用
- Kennedy NA, Lin S, Goodhand JR, et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. 2021. PMID: 33903149. doi:10.1136/gutjnl-2021-324789
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。